Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update

Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin Invested record $50 million in research and development initiatives across brain, thoracic and abdominal programs ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2021, highlighting commercial strength and …

Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Awards totaling more than $2 million aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint …

Novocure to Report Second Quarter 2021 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2021 on Thursday, July 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2021, at …